studyconnect.org

What It Is

Study Connect positions itself as a boutique CRO and fractional clinical-regulatory leadership provider for MedTech and life sciences companies. It is not a SaaS platform in the traditional sense; instead, it is a service-based company centered on expert teams, clinical study execution, FDA regulatory strategy, commercialization, and fundraising support, helping medical device companies move from concept to market.

Core Capabilities

The key areas highlighted on its website include FDA regulatory strategy, 510(k), De Novo, Breakthrough Device applications, Pre-sub planning, Q-submissions, and FDA communication strategy. It also offers clinical trial design and execution, market access, go-to-market support, investor materials preparation, expert networks, scientific advisors, and advisory board development. Its “fractional support” model is suitable for companies that have not yet built internal clinical or regulatory teams, filling gaps with external senior talent. AI workflows are used to streamline research and operational processes, but the site does not specify the exact software format, model capabilities, or boundaries of automation.

Pricing and Engagement

Study Connect does not publish a pricing table. The website mentions that engagement models may include hourly fees, monthly retainers, fixed project fees, or milestone-based payments. Scope, deliverables, timelines, and pricing are clarified after a discovery meeting. It offers a free 25/30-minute Discovery Call and says it typically responds within 1 business day, with most projects able to start within 1–2 weeks.

Pros and Cons

Its strengths lie in its clear vertical focus and coverage of key milestones for medical devices, from clinical evidence and FDA pathways to fundraising and commercialization. The fractional team model is flexible and well suited to early-stage companies looking to control fixed headcount costs. The website also cites 5+ FDA Breakthrough Device applications, clinical milestones for 20+ companies, and a network of 100+ KOLs and U.S. practitioners. The main drawback is that it is not standard enterprise software: there is no public cloud product, third-party integrations, permission system, API, or developer documentation. Data security, privacy, and compliance certifications are also not disclosed, and pricing transparency is limited.

Who It’s For and Access from China

Study Connect is best suited for medical device companies, AI healthcare teams, diagnostic imaging companies, and similar organizations preparing for FDA engagement or entry into the U.S. market—especially early-stage companies that need external clinical/regulatory leadership and CRO execution capabilities. Information on access from China and cross-border payments is unknown. For China-based registration and clinical work, companies may also evaluate local CROs such as Tigermed and R&G PharmaStudies; for the U.S. FDA pathway, Study Connect can be compared with international CROs such as IQVIA, Medpace, and Parexel.